

## **Supplementary Material**

### **Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel**

**Eric van der Putten<sup>1</sup>, Katja Wosikowski<sup>1</sup>, Jos H. Beijnen<sup>2</sup>, Gábor Imre<sup>3</sup>, Colin R. Freund<sup>1</sup>**

<sup>1</sup>Modra Pharmaceuticals B.V., Amsterdam 1083 HN, the Netherlands.

<sup>2</sup>Department of Pharmacy & Pharmacology, Netherlands Cancer Institute - Antoni van Leeuwenhoek, Amsterdam 1066 CX, the Netherlands.

<sup>3</sup>SOLVO Biotechnology, Budapest H-1117, Hungary.

**Correspondence to:** Eric van der Putten, Modra Pharmaceuticals B.V., Barbara Strozziilaan 201, 1083 HN, Amsterdam, the Netherlands. E-mail:

[eric.vanderputten@modrapharmaceuticals.com](mailto:eric.vanderputten@modrapharmaceuticals.com)

**Supplementary Table 1. Substrate assessment of docetaxel for P-gp in the Caco-2 assay**

<b>Compound</b>	<b>Concentration</b>	<b>ER (Average <math>\pm</math> EP)</b>	<b>Substrate</b>
<b>Incubation 60 min</b>			
Docetaxel	10 $\mu$ M	31.80 $\pm$ 1.54	
+ Valspodar	+ 10 $\mu$ M	1.04 $\pm$ 0.09	Yes
+ Ritonavir	+ 50 $\mu$ M	1.24 $\pm$ 0.09	
Docetaxel	5 $\mu$ M	69.46 $\pm$ 13.24	
+ Valspodar	+ 10 $\mu$ M	2.49 $\pm$ 0.82	Yes
+ Ritonavir	+ 50 $\mu$ M	2.00 $\pm$ 0.34	
<b>Incubation 120 min</b>			
Docetaxel	10 $\mu$ M	32.66 $\pm$ 5.35	
+ Valspodar	+ 10 $\mu$ M	1.07 $\pm$ 0.16	Yes
+ Ritonavir	+ 50 $\mu$ M	1.08 $\pm$ 0.03	
Docetaxel	5 $\mu$ M	43.85 $\pm$ 3.80	
+ Valspodar	+ 10 $\mu$ M	1.06 $\pm$ 0.17	Yes
+ Ritonavir	+ 50 $\mu$ M	1.60 $\pm$ 0.28	

ER: Efflux ratio; EP: error propagation.